Quigley now ProPhase Labs
This article was originally published in The Tan Sheet
Executive Summary
The maker of Cold-EEZE zinc lozenges changes its name to ProPhase Labs Inc., following a shareholder vote May 5. Company shares now trade on NASDAQ under the symbol "PRPH." CEO Ted Karkus said the corporate re-branding will include redesigned packaging for Cold-EEZE and Kids-EEZE cold remedies. Since ousting founder Guy Quigley in June 2009, Karkus has shaken things up at the Doylestown, Pa., firm, including forming an OTC joint venture with delivery technology developer Phosphagenics (1"The Tan Sheet" March 29, 2010)
You may also be interested in...
ProPhase pares costs, preps relaunches
The OTC firm, formerly known as Quigley, discontinues a candy product line and shutters a contract manufacturing facility, reducing first-quarter operating costs and expenses 51 percent to $2.2 million. ProPhase Labs' net sales in the January-March period also dropped 50.4 percent to $2 million, but its year-over-year net loss was halved to $1.1 million. Sales took a hit as retailer orders of cold and flu products, such as ProPhase's Cold-EEZE zinc lozenges, were front-loaded in fourth quarter 2009, according to CEO Ted Karkus. He added May 17 ProPhase is entering "a wonderful new phase," with redesigned packaging, a new mint frost Cold-EEZE flavor and the planned reintroduction of a Kids-EEZE non-liquid product line (1"The Tan Sheet" May 10, 2010, In Brief)
Quigley Counts On Delivery Technology Partner To Expand Consumer Business
Quigley Corp. picks delivery technology developer Phosphagenics to help grow its sales after curbing its Rx research to expand its consumer business beyond Cold-EEZE and its other natural health care lines
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.